20 Participants Needed

Sphere-9 Catheter for VT

(Sphere-9 VT Trial)

Recruiting at 3 trial locations
JT
Overseen ByJosh Treadway
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Medtronic Cardiac Rhythm and Heart Failure
Must be taking: Antiarrhythmics
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, it mentions that participants should have experienced ventricular tachycardia despite being on certain antiarrhythmic drugs, which suggests you may continue your current medication.

Is the Sphere-9 Catheter safe for use in humans?

The available research does not provide specific safety data for the Sphere-9 Catheter, but it highlights the importance of monitoring and reporting adverse effects in similar catheter ablation procedures to ensure patient safety.12345

What is the purpose of this trial?

Sphere-9 VT is a prospective, multi-center, non-randomized, unblinded feasibility study. Adult subjects with recurrent, sustained, monomorphic ventricular tachycardia due to prior myocardial infarction will be enrolled and treated with the Sphere-9 Catheter and Affera Ablation System.

Research Team

VR

Vivek Reddy, MD

Principal Investigator

Icahn School of Medicine at Mount Sinai

Eligibility Criteria

This trial is for adults aged 18-85 who've had a heart attack before and now suffer from a type of irregular heartbeat called ventricular tachycardia, which hasn't improved with certain medications or devices designed to control heart rhythm. Participants must have experienced at least one episode in the past six months and be willing to follow the study's procedures.

Inclusion Criteria

I am willing and able to follow all testing requirements.
I have had a fast heart rate that didn't stop despite taking specific heart medications or having a device implanted.
I am willing and able to agree to participate in the study.
See 3 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants are treated with the Sphere-9 Catheter and Affera Ablation System for ventricular tachycardia

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 months
Multiple visits (in-person)

Treatment Details

Interventions

  • Sphere-9 Catheter with the Affera Mapping and Ablation System
Trial Overview The Sphere-9 VT study is testing how safe and effective the Sphere-9 Catheter combined with the Affera Ablation System is in treating recurrent ventricular tachycardia that occurs after a previous heart attack. This non-randomized trial will enroll participants to undergo this specific treatment without comparing it to other treatments.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Ventricular tachycardia catheter ablationExperimental Treatment1 Intervention
Ablation using the Sphere-9 Catheter with the Affera Mapping and Ablation System

Find a Clinic Near You

Who Is Running the Clinical Trial?

Medtronic Cardiac Rhythm and Heart Failure

Lead Sponsor

Trials
206
Recruited
137,000+
Geoff Martha profile image

Geoff Martha

Medtronic Cardiac Rhythm and Heart Failure

Chief Executive Officer since 2020

MBA from University of Minnesota

Dr. Kweli Thompson profile image

Dr. Kweli Thompson

Medtronic Cardiac Rhythm and Heart Failure

Chief Medical Officer since 2022

MD from Harvard Medical School

Medtronic Cardiac Ablation Solutions

Lead Sponsor

Trials
29
Recruited
16,000+

References

Global multielectrode contact-mapping plus ablation with a single catheter in patients with atrial fibrillation: Global AF study. [2020]
Initial clinical experience of atrial fibrillation ablation guided by a cryoballoon-compatible, magnetic-based circular catheter. [2023]
Circular mapping catheter entrapment in the mitral valve apparatus: a previously unrecognized complication of focal atrial fibrillation ablation. [2019]
PV Isolation Using a Spherical Array PFA Catheter: Preclinical Assessment and Comparison to Radiofrequency Ablation. [2023]
Safety of Catheter Ablation for Atrial Fibrillation in Patients With Prior Cerebrovascular Events. [2021]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceยทPrivacy PolicyยทCookiesยทSecurity